Search

Your search keyword '"Davidson, Jaime"' showing total 158 results
Start Over Author "Davidson, Jaime" Search Limiters Available in Library Collection
158 results on '"Davidson, Jaime"'

6. Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.

Author

Davidson, Jaime A, Sukor, Norlela, Hew, Fen‐Lee, Mohamed, Mafauzy, and Hussein, Zanariah

Subjects
*SODIUM-glucose cotransporters, *SODIUM-glucose cotransporter 2 inhibitors, *TYPE 2 diabetes, *GLYCEMIC control, *BODY mass index
Abstract

The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger‐onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β‐cell function, among Asian populations. Sodium–glucose cotransporter 2 inhibitors have been shown to confer favorable effects in type 2 diabetes mellitus patients, such as improved glycemic control, weight and blood pressure reduction, and importantly, cardiorenal benefits. Sodium–glucose cotransporter 2 inhibitors are generally well‐tolerated, and have a well‐defined safety profile based on evidence from numerous clinical trials and post‐marketing pharmacovigilance reporting. To our knowledge, this review is the first to provide a comprehensive coverage of the adverse events of sodium–glucose cotransporter 2 inhibitors, as well as their management and counseling aspects for Asian type 2 diabetes mellitus populations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Author

Udell, Jacob A., Bhatt, Deepak L., Braunwald, Eugene, Cavender, Matthew A., Mosenzon, Ofri, Steg, Ph. Gabriel, Davidson, Jaime A., Nicolau, Jose C., Corbalan, Ramon, Hirshberg, Boaz, Frederich, Robert, Im, KyungAh, Umez-Eronini, Amarachi A., He, Ping, McGuire, Darren K., Leiter, Lawrence A., Raz, Itamar, and Scirica, Benjamin M.

Published
2015
Full Text
View/download PDF

24. Guías ALAD basadas en evidencias para el diagnóstico y el tratamiento de la polineuropatía sensitivomotora diabética 2019 (Grupo NeuroALAD)

Author

Mesa-Pérez, José Agustín, primary, Odriozola, Ariel, additional, Antonucci, Ricardo, additional, Campillo, Nalini, additional, Márquez, Gustavo, additional, Costa Gil, José, additional, Ziegler, Dan, additional, Hernández, Sergio, additional, Faget, Orestes, additional, Davidson, Jaime, additional, and Ibrahim, Ammar, additional

Published
2019
Full Text
View/download PDF

25. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

Author

Koval Stephen, Davidson Jaime, Sharma Arya M, and Lacourcière Yves

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background The Study of Micardis (telmisartan) in Overweight/Obese patients with Type 2 diabetes and Hypertension (SMOOTH) compared hydrochlorothiazide (HCTZ) plus telmisartan or valsartan fixed-dose combination therapies on early morning blood pressure (BP), using ambulatory BP monitoring (ABPM). Methods SMOOTH was a prospective, randomized, open-label, blinded-endpoint, multicentre trial. After a 2- to 4-week, single-blind, placebo run-in period, patients received once-daily telmisartan 80 mg or valsartan 160 mg for 4 weeks, with add-on HCTZ 12.5 mg for 6 weeks (T/HCTZ or V/HCTZ, respectively). At baseline and week 10, ambulatory blood pressure (ABP) was measured every 20 min and hourly means were calculated. The primary endpoint was change from baseline in mean ambulatory systolic and diastolic blood pressure (SBP; DBP) during the last 6 hours of the 24-hour dosing interval. Results In total, 840 patients were randomized. At week 10, T/HCTZ provided significantly greater reductions versus V/HCTZ in the last 6 hours mean ABP (differences in favour of T/HCTZ: SBP 3.9 mm Hg, p < 0.0001; DBP 2.0 mm Hg, p = 0.0007). T/HCTZ also produced significantly greater reductions than V/HCTZ in 24-hour mean ABP (differences in favour of T/HCTZ: SBP 3.0 mm Hg, p = 0.0002; DBP 1.6 mm Hg, p = 0.0006) and during the morning, daytime and night-time periods (p < 0.003). Both treatments were well tolerated. Conclusion In high-risk, overweight/obese patients with hypertension and type 2 diabetes, T/HCTZ provides significantly greater BP lowering versus V/HCTZ throughout the 24-hour dosing interval, particularly during the hazardous early morning hours.

Published
2007
Full Text
View/download PDF

27. A participatory approach to developing a holistic and interdisciplinary adaptive capacity index for urban livelihoods

Author

Davidson, Jaime, Ziervogel, Gina, and Visser, Martine

Subjects
Environment, Society and Sustainability
Abstract

Evaluating the success of the growing number of climate adaptation initiatives is challenging. Assessment of adaptive capacity has been used to focus, prioritise and track the progress of adaptation interventions as well as to identify key barriers to and opportunities for implementing adaptation. Many adaptive capacity assessments have relied on secondary data and expert judgement. Given the call in climate change research and practice for bottom-up approaches that value communities' insight, it is clear that more participatory approaches for the assessment of adaptive capacity need to be developed. This research aims to address this gap by developing an adaptive capacity index that adopts a mixed methods approach and prioritises input from local stakeholders. Many adaptive capacity assessments have focussed on rural areas where livelihoods are directly exposed to climate variability. There is growing recognition that increasing numbers of people are settling in urban areas and many of these livelihoods are often at the margin. This thesis focuses on urban livelihoods where a more holistic understanding of adaptive capacity is required which recognises that a community's capacity to adjust to climatic stressors is interlinked to its capacity to adjust to environmental, social, economic and political challenges. An adaptive capacity index is developed in this thesis that includes and characterises the more subjective determinants of adaptive capacity, rather than giving precedence to material resources as the key determinant of a community's adaptive capacity. To achieve this richer understanding, the index is informed by a framework that incorporates aspects of individuals' agency and social cohesion. Using a case study of four towns in the Bergrivier Municipality, South Africa, this research develops an index of adaptive capacity that is holistic, collaborative and interdisciplinary. The scores generated by the index are analysed using statistical and regression analyses that are contextualised by stakeholders' inputs to explore the variation in adaptive capacity across socially differentiated groups. Key insights from these analyses relate to the variation in adaptive capacity between the four towns and differences in the adaptive capacity of males and females. Interestingly, the analyses revealed the absence of a positive correlation between schooling level and both adaptive capacity and wellbeing variables which could be attributed to limited economic opportunities in the area, particularly for high-skilled workers. The analyses also highlighted the need to support initiatives that strengthen the social cohesion within the community to improve the inclusion of marginal demographic groups. The thesis reflects on the participatory and collaborative research process, finding that combining quantitative and qualitative data through an interdisciplinary process has the potential to provide an index that is more reflective of subjective capacity. This more holistic understanding of adaptive capacity can align with the field of wellbeing, to offer valuable insight into building adaptive capacity for urban livelihoods that is grounded in both academic and applied fields.

Published
2016

30. Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitus

Author

Davidson,Jaime A, Rosales,Aracely, Shillington,Alicia, Bailey,Robert, Kabir,Chris, Umpierrez,Guillermo, Davidson,Jaime A, Rosales,Aracely, Shillington,Alicia, Bailey,Robert, Kabir,Chris, and Umpierrez,Guillermo

Abstract

Jaime A Davidson,1 Aracely Rosales,2 Alicia C Shillington,3 Robert A Bailey,4 Chris Kabir,3 Guillermo E Umpierrez51Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Rosales Communications, Philadelphia, PA, USA; 3EPI-Q, Inc., Oakbrook, IL, USA; 4Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ, USA; 5Division of Endocrinology and Metabolism, Emory University, Atlanta, Georgia, GA, USAPurpose: To describe the cultural and linguistic adaptation and Spanish translation of an English-language patient decision aid (PDA) for use in supporting shared decision-making in Hispanics/Latinos with type 2 diabetes mellitus (T2DM), a group at a high risk for complications.Patients and methods: A steering committee of endocrinologists, a primary care physician, a certified diabetes educator, and a dietician, each with extensive experience in providing care to Hispanics/Latinos was convened to assess a PDA developed for English-speaking patients with T2DM. English content was reviewed for cultural sensitivity and appropriateness for a Hispanic/Latino population. A consensus-building process and iterative version edits incorporated clinician perspectives. The content was adapted to be consistent with traditional Hispanic/Latino cultural communication precepts (eg, avoidance of hostile confrontation; value for warm interaction; respect for authority; value of family support for decisions). The PDA was translated by native-speaking individuals with diabetes expertise.Results: The PDA underwent testing during cognitive interviews with ten Spanish-speaking Hispanics/Latinos with T2DM to ensure that the content is reflective of the experience, understanding, and language Hispanic/Latino patients use to describe diabetes and treatment. Content edits were made to assure a literacy level appropriate to the audience, and the PDA was produced for online video dissemination.Conclusion: High-quality, well-d

Published
2015

31. Incidence of Reported Gastrointestinal and Hypoglycemic Symptoms with Metformin/Glyburide Tablets as First-Line Therapy in Type 2 Diabetes

Author

GARBER, ALAN, DAVIDSON, JAIME, Anderson, Robert, American businessperson and engineer, and PIPER, BETH ANNE

Subjects
Metformin -- Evaluation, Glibenclamide -- Evaluation, Type 2 diabetes -- Drug therapy, Hypoglycemic agents -- Adverse and side effects, Health
Abstract

Combination therapy with metformin (Met) and glyburide (Gly) is often used to treat patients with type 2 diabetes. Met is associated with gastrointestinal (GI) symptoms, and Gly may cause hypoglycemia. [...]

Published
2000

32. Metformin/Glyburide is Safe and Well Tolerated as First-Line Therapy in Patients With Type 2 Diabetes

Author

DAVIDSON, JAIME, SCHNEIDER, STEPHEN, GARBER, ALAN, and MERTEN, JOHN

Subjects
Type 2 diabetes -- Drug therapy, Metformin -- Evaluation, Glibenclamide -- Evaluation, Health
Abstract

Metformin (Met) and glyburide (Gly) are often used in combination to treat patients with type 2 diabetes. A fixed combination metformin/glyburide (M/G) tablet has been developed and evaluated in clinical [...]

Published
2000

33. Metformin/Glyburide Tablets As First-Line Treatment In Type 2 Diabetes: Distribution Of [HbA.sub.1c] Response

Author

DAVIDSON, JAIME, GARBER, ALAN, MOORADIAN, ARSHAG, SCHNEIDER, STEPHEN, and HENRY, DAVID

Subjects
Metformin -- Evaluation, Glibenclamide -- Evaluation, Type 2 diabetes -- Drug therapy, Health
Abstract

The pathogenesis of type 2 diabetes involves both impaired insulin secretion and increased insulin resistance. Use of two oral antidiabetic agents with complementary mechanisms of action may result in a [...]

Published
2000

34. Effect Of Metformin/Glyburide Tablets On HbA1c In First-Line Treatment Of Type 2 Diabetes

Author

GARBER, ALAN, DAVIDSON, JAIME, MOORADIAN, ARSHAG, and PIPER, BETH ANNE

Subjects
Metformin -- Evaluation, Glibenclamide -- Evaluation, Glycosylated hemoglobin -- Measurement, Type 2 diabetes -- Drug therapy, Health
Abstract

Type 2 diabetes results from the dual defects of insulin resistance and progressive inadequacy of pancreatic insulin secretion. Traditional first-line therapy has focused on the management of one or the [...]

Published
2000

35. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Gabriel, additional, and Bhatt, Deepak L., additional

Published
2015
Full Text
View/download PDF

37. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Author

Udell, Jacob A., primary, Bhatt, Deepak L., additional, Braunwald, Eugene, additional, Cavender, Matthew A., additional, Mosenzon, Ofri, additional, Steg, Ph. Gabriel, additional, Davidson, Jaime A., additional, Nicolau, Jose C., additional, Corbalan, Ramon, additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, He, Ping, additional, McGuire, Darren K., additional, Leiter, Lawrence A., additional, Raz, Itamar, additional, and Scirica, Benjamin M., additional

Published
2014
Full Text
View/download PDF

38. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.

Author

May-yun Wang, Xinxin Yu, Young Lee, Shiuhwei Chen, Davidson, Jaime A., Scherer, Philipp E., Holland, William L., Unger, Roger H., Roth, Michael G., McCorkle, Sara Kay, Wang, Zhao V., and Jianping Li

Subjects
DAPAGLIFLOZIN, GLUCAGON, SODIUM-glucose cotransporters, DIABETES, ANIMAL models in research
Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of antidiabetic drug used for the treatment of diabetes. These drugs are thought to lower blood glucose by blocking reabsorption of glucose by SGLT2 in the proximal convoluted tubules of the kidney. To investigate the effect of inhibiting SGLT2 on pancreatic hormones, we treated perfused pancreata from rats with chemically induced diabetes with dapagliflozin and measured the response of glucagon secretion by alpha cells in response to elevated glucose. In these type 1 diabetic rats, glucose stimulated glucagon secretion by alpha cells; this was prevented by dapagliflozin. Two models of type 2 diabetes, severely diabetic Zucker rats and db/db mice fed dapagliflozin, showed significant improvement of blood glucose levels and glucose disposal, with reduced evidence of glucagon signaling in the liver, as exemplified by reduced phosphorylation of hepatic cAMP-responsive element binding protein, reduced expression of phosphoenolpyruvate carboxykinase 2, increased hepatic glycogen, and reduced hepatic glucose production. Plasma glucagon levels did not change significantly. However, dapagliflozin treatment reduced the expression of the liver glucagon receptor. Dapagliflozin in rodents appears to lower blood glucose levels in part by suppressing hepatic glucagon signaling through down-regulation of the hepatic glucagon receptor. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

39. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Ph. Gabriel, additional, and Bhatt, Deepak L., additional

Published
2014
Full Text
View/download PDF

41. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL

Author

Scirica, Benjamin, primary, Bhatt, Deepak, additional, Braunwald, Eugene, additional, Raz, Itamar, additional, Steg, Philippe, additional, Davidson, Jaime, additional, Cavender, Matthew, additional, Hirshberg, Boaz, additional, Umez-Eronini, Amarachi, additional, Im, Kelly, additional, Jarolim, Petr, additional, and Morrow, David, additional

Published
2014
Full Text
View/download PDF

47. Consenso de expertos para el manejo de la neuropatía diabética.

Author

Escaño-Polanco, Félix Manuel, Odriozola, Ariel, Davidson, Jaime, Pedrosa, Hermelinda, Fuente, Gabriela, Márquez, Gustavo, Daniel Braver, José, Pérez-Monteverde, Armando, Litwak, Leon, Olimpo Mendivil, Carlos, Clemente Rolím, Luiz, and Schmid, Helena

Abstract

Copyright of Revista de la ALAD is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2016

48. Guidelines for the treatment and management of new-onset diabetes after transplantation

Author

Wilkinson, Alan, Davidson, Jaime, Dotta, Francesco, Home, Philip P.D., Keown, Paul, Kiberd, Bryce, Jardine, Alan G.Alan, Levitt, Naomi, Marchetti, Piero, Markell, Mariana, Naicker, Sarala, O'Connell, Philip, Schnitzler, Mark, Standl, Eberhard, Torregosa, Jose-Vicente, Uchida, Kazuharu, Valantine, Hannah, Villamil, Federico, Vincenti, Flavio, Wissing, Karl Martin, Wilkinson, Alan, Davidson, Jaime, Dotta, Francesco, Home, Philip P.D., Keown, Paul, Kiberd, Bryce, Jardine, Alan G.Alan, Levitt, Naomi, Marchetti, Piero, Markell, Mariana, Naicker, Sarala, O'Connell, Philip, Schnitzler, Mark, Standl, Eberhard, Torregosa, Jose-Vicente, Uchida, Kazuharu, Valantine, Hannah, Villamil, Federico, Vincenti, Flavio, and Wissing, Karl Martin

Abstract

Although graft and patient survival after solid organ transplantation have improved markedly in recent years, transplant recipients continue to experience an increased prevalence of cardiovascular disease (CVD) compared with the general population. A number of factors are known to impact on the increased risk of CVD in this population, including hypertension, dyslipidemia and diabetes mellitus. Of these factors, new-onset diabetes after transplantation has been identified as one of the most important, being associated with reduced graft function and patient survival, and increased risk of graft loss. In 2003, International Consensus Guidelines on New-onset Diabetes after Transplantation were published, which aimed to establish a precise definition and diagnosis of the condition and recommend management strategies to reduce its occurrence and impact. These updated 2004 guidelines, developed in consultation with the International Diabetes Federation (IDF), extend the recommendations of the previous guidelines and encompass new-onset diabetes after kidney, liver and heart transplantation. It is hoped that adoption of these management approaches pre- and post-transplant will reduce individuals' risk of developing new-onset diabetes after transplantation as well as ameliorating the long-term impact of this serious complication. © Blackwell Munksgaard, 2005., SCOPUS: re.j, FLWIN, info:eu-repo/semantics/published

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results